Drugs in Dev.
Sleep
Discovery

McGill, industry, CQDM and Brain Canada collaborate for drug discovery
Details : The funding aims to advance the discovery of investigational products that have made significant progress in development and could help treat insomnia and neuropathic pain.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 03, 2024

Details : The joint venture will initially focus on accelerating the discovery, preclinical and clinical development of novel pharmacologic solutions designed to address the complex pathology of obstructive sleep apnea.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 31, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Sleep
Study Phase : Discovery
Sponsor : Centessa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
X-Chem Announces Achievement of Milestone In Orexia Collaboration
Details : After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin posit...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 22, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Sleep
Highest Development Status : Discovery
Sponsor : Centessa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration

Details : Sosei Heptares solves structure of the agonist bound orexin OX2 receptor and identifies small molecule binding site using unique StaR® technology and structure-based approach.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 07, 2020
